Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
Previous Symbol
CUSIPN/A
Phone513-579-9911
Debt
Debt-to-Equity Ratio0.25
Current Ratio0.66
Quick Ratio0.66
Price-To-Earnings
Trailing P/E Ratio36.47
Forward P/E Ratio22.09
P/E Growth1.38
Sales & Book Value
Annual Sales$436.15 million
Price / Sales4.53
Cash Flow$2.63 per share
Price / Cash21.08
Book Value$15.77 per share
Price / Book3.52
Profitability
EPS (Most Recent Fiscal Year)$1.52
Net Income$39.12 million
Net Margins10.84%
Return on Equity15.86%
Return on Assets8.74%
Miscellaneous
Employees2,500
Outstanding Shares35,600,000
Market Cap$1.97 billion
OptionableOptionable
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings results on Thursday, November, 1st. The company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.63 by $0.04. The firm had revenue of $179 million for the quarter, compared to the consensus estimate of $175.07 million. Medpace had a return on equity of 15.86% and a net margin of 10.84%. The company's revenue for the quarter was up 44.4% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS. View Medpace's Earnings History.
When is Medpace's next earnings date?
What guidance has Medpace issued on next quarter's earnings?
Medpace updated its FY18 earnings guidance on Monday, October, 29th. The company provided earnings per share (EPS) guidance of $2.76-2.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.48. Medpace also updated its FY 2018 guidance to $2.76-2.82 EPS.
What price target have analysts set for MEDP?
7 Wall Street analysts have issued 12-month price targets for Medpace's shares. Their forecasts range from $35.00 to $63.00. On average, they anticipate Medpace's share price to reach $42.8333 in the next twelve months. This suggests that the stock has a possible downside of 22.7%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medpace.
Has Medpace been receiving favorable news coverage?
Media headlines about MEDP stock have been trending somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a news impact score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next few days.
Are investors shorting Medpace?
Medpace saw a decrease in short interest in October. As of October 15th, there was short interest totalling 614,007 shares, a decrease of 26.7% from the September 28th total of 838,229 shares. Based on an average daily volume of 485,404 shares, the short-interest ratio is currently 1.3 days. Approximately 2.3% of the shares of the stock are sold short. View Medpace's Current Options Chain.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), Vitality Biopharma (VBIO) and BIOQUAL (BIOQ).
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 62)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.41%), Acadian Asset Management LLC (4.12%), Laurion Capital Management LP (3.11%), Renaissance Technologies LLC (2.20%), Fuller & Thaler Asset Management Inc. (1.75%) and Deutsche Bank AG (1.43%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., State Board of Administration of Florida Retirement System, Point72 Asset Management L.P., Fisher Asset Management LLC, Alambic Investment Management L.P., PNC Financial Services Group Inc., Systematic Financial Management LP and LSV Asset Management. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Laurion Capital Management LP, Deutsche Bank AG, Penserra Capital Management LLC, Bank of New York Mellon Corp and Man Group plc. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $55.44.
How big of a company is Medpace?
Medpace has a market capitalization of $1.97 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
